Table 3.
Comparison with other studies
| Study | No of patients | Oxaliplatin (mg/m2) | Hypersensitivity all grade (%) (95% CI) |
Hypersensitivity G3–4 (%) |
|---|---|---|---|---|
| Brandi et al26 | 124 | – | 13.7 (8.2–21.0) | 7.3 |
| Andre et al3 | 1,108 | 820 | 10.3 (8.6–12.2) | 2.9 |
| Gowda et al27 | 169 | – | 18.9 (13.3–25.7) | <1 |
| Siu et al24 | 180 | – | 15 (10.1–21.1) | 2.2 |
| Shibata et al28 | 125 | FOLFOX 8 cycles | 16.8 (10.7–24.5) | 4 |
| Seki et al25 | 108 | 560 | 22.3 (14.8–31.2) | 9.3 |
| Parel et al5 | 191 | 546 | 8.9 (5.3–13.9) | 1.6 |
| Our study | 73 | 851 | 4.1 (0.9–11.5) | 0 |
Abbreviations: CI, confidence interval; FOLFOX, folinic acid, fluorouracil, and oxaliplatin.